Table 3.

Medical treatment at enrollment and at hospital discharge

	Overall population		Women		Men		p value (sex)	p value (visit)
	Enrollment	Discharge	Enrollment	Discharge	Enrollment	Discharge
Antihypertensive drug, all, n (%)	3,013 (89.9)	3,287 (98.1)	697 (90.2)	754 (97.5)	2,316 (89.8)	2,533 (98.2)	0.8	<0.001
ACE inhibitor, n (%)	1,902 (56.7)	2,299 (68.6)	405 (52.4)	506 (65.5)	1,497 (58.0)	1,793 (69.5)	<0.001	<0.001
AT1 receptor blocker, n (%)	685 (20.4)	742 (22.1)	167 (21.6)	181 (23.4)	518 (20.1)	561 (21.8)	0.2	0.09
Beta-blocker, n (%)	2,439 (72.8)	2,884 (86.0)	583 (75.4)	675 (87.3)	1,856 (72.0)	2,209 (85.7)	0.03	<0.001
Calcium channel blocker, n (%)	258 (7.7)	305 (9.1)	69 (8.9)	79 (10.2)	189 (7.3)	226 (8.8)	0.06	0.04
Loop diuretic, n (%)	625 (18.6)	723 (21.6)	166 (21.5)	196 (25.4)	459 (17.8)	527 (20.4)	<0.001	0.003
Diuretic, other (thiazides, potassium-sparing), n (%)	1,178 (35.1)	1,358 (40.5)	290 (37.5)	332 (42.9)	888 (34.4)	1,026 (39.8)	0.03	<0.001
Platelet aggregation inhibitor and/or anticoagulant, n (%)	2,794 (83.4)	3,237 (96.6)	634 (82.0)	745 (96.4)	2,160 (83.8)	2,492 (96.6)	0.2	<0.001
Platelet aggregation inhibitor ASA, n (%)	2,569 (76.6)	3,062 (91.3)	585 (75.7)	695 (89.9)	1,984 (76.9)	2,367 (91.8)	0.1	<0.001
Platelet aggregation inhibitor clopidogrel, n (%)	1,441 (43.0)	2,330 (69.5)	322 (41.7)	548 (70.9)	1,119 (43.4)	1,782 (69.1)	0.9	<0.001
Anticoagulant (heparin, vitamin K antagonist and/or NOAC), n (%)	548 (16.3)	695 (20.7)	128 (16.6)	169 (21.9)	420 (16.3)	526 (20.4)	0.4	<0.001
Statins, n (%)	2,282 (68.1)	2,817 (84.0)	512 (66.2)	633 (81.9)	1,770 (68.6)	2,184 (84.7)	0.03	<0.001

ACE, angiotensin-converting enzyme; ASA, acetylsalicylic acid; AT1, angiotensin II receptor type 1; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; NOAC, “non-vitamin K antagonist” oral anticoagulant